AngioDynamics (ANGO) Tops Q3 EPS by 4c, Offers Guidance

AngioDynamics (NASDAQ: ANGO) reported Q3 EPS of $0.02, $0.04 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $71.2 million versus the consensus estimate of $68.95 million.

GUIDANCE:

AngioDynamics sees FY2021 EPS of $0.04-$0.06, versus the consensus of $0.01. AngioDynamics sees FY2021 revenue of $285-288 million, versus the consensus of $283.5 million.

For earnings history and earnings-related data on AngioDynamics (ANGO) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary